Document:

Exhibit 10.161

Price Legacy keeps the proceeds of the sale of the first 200,000 shares of MACE.
Price Legacy keeps title to the remaining  1,675,000 shares; the restrictions on
sale are lifted by MACE as sales are made and as proceeds are paid to MACE;  and
as Price Legacy  proceeds to sell these shares it splits net proceeds 50:50 with
MACE.  At any time so long as any of these shares remain unsold MACE can ask for
1/2 of these  shares  from  Price  Legacy  and at such  time  MACE will lift the
restrictions on the shares remaining with Price Legacy.

Agreed:                                     Agreed:
-------                                     -------

/s/ Jack McGrory                            /s/ Louis D. Paolino, Jr.
----------------                            -------------------------
Jack McGrory                                Louis D. Paolino, Jr.
CEO                                         C.E.O
PriceLegacy                                 Mace Security International, Inc.EXHIBIT 4.1

                         COMMON STOCK PURCHASE AGREEMENT

THIS COMMON STOCK PURCHASE AGREEMENT ("Agreement") is made and entered
into as of April 23, 2004 (the "Effective Date"), by and between GERON
CORPORATION, a Delaware corporation having its principal place of business at
230 Constitution Drive, Menlo Park, California 94025 ("Geron"), and
TRANSGENOMIC, INC., a Delaware corporation having its principal place of
business at 12325 Emmet Street, Omaha, Nebraska 68164 ("Transgenomic").

     A.   Geron and Transgenomic are the parties to that certain Supply
          Agreement dated as of June 15, 2002 (the "Supply Agreement"), and
          related Addendum Agreements ("Addendum Agreement") under which Geron
          has agreed to purchase certain products from Transgenomic and
          Transgenomic has agreed to supply such products to Geron on the terms
          set forth therein.

     B.   Pursuant to Addendum Agreement No. 5 effective December 19, 2003,
          Geron may pay the purchase price of products by delivery of shares of
          Geron's Common Stock.

THE PARTIES AGREE AS FOLLOWS:

     1.    ISSUANCE OF SHARES; ADJUSTMENTS.

          1.1  As payment of the Second Installment specified in Addendum
               Agreement No. 5, Geron will issue and deliver one or more
               certificates for 26,460 shares (the "Group 1 Shares") and one or
               more certificates for 49,557 shares (the "Group 2 Shares"). Upon
               issuance and delivery of the certificate(s) for the Group 1
               Shares and the Group 2 Shares (collectively, the "Shares"), all
               Shares shall be duly authorized and validly issued and represent
               fully paid shares of Geron's Common Stock.

     2.    CLOSING; DELIVERY.

          2.1  The consummation of the transaction contemplated by this
               Agreement (a "Closing") shall be held at such time and place as
               is mutually agreed upon between the parties, but in any event no
               later than three (3) business days after the Effective Date of
               this Agreement (the "Closing Date"). At the Closing, Geron shall
               deliver to Transgenomic one or more certificates representing all
               of the Shares, which Shares shall be issued in the name of
               Transgenomic or its designee and in such denominations as
               Transgenomic shall specify.

          2.2  Geron's obligations to issue and deliver the stock certificate(s)
               representing the Shares to Transgenomic at the Closing shall be
               subject to the following conditions, which may be waived by
               Geron:

               2.2.1 the covenants and obligations that Transgenomic is required
                    to perform or to comply with pursuant to this Agreement, at
                    or prior to the Closing, must have been duly performed and
                    complied with in all material respects; and

               2.2.1 the representations and warranties made by Transgenomic
                    herein shall be true and correct in all material respects as
                    of the Closing Date.

          2.3  Transgenomic's obligation to accept delivery of the stock
               certificate(s) representing the Shares at the Closing shall be
               subject to the following conditions, any one or more of which may
               be waived by Transgenomic:

               2.3.1 the covenants and obligations that Geron is required to
                    perform or to comply with pursuant to this Agreement and
                    under the Common Stock Purchase Agreement between the
                    parties hereto dated January 21, 2004, at or prior to the
                    Closing, must have been duly performed and complied with in
                    all material respects;

                                       1
<PAGE>

               2.3.2 Geron shall have available under its Certificate of
                    Incorporation sufficient authorized shares of Common Stock
                    to issue the Shares to Transgenomic; and

               2.3.3 the representation and warranties made by the Geron herein
                    shall be true and correct in all material respects as of any
                    Closing Date.

     3.   RESTRICTIONS ON RESALE OF SHARES.

               3.1  Legends. Transgenomic understands and acknowledges that the
                    Shares are not registered under the Securities Act of 1933
                    (the "Act"), and that under the Act and other applicable
                    laws Transgenomic may be required to hold such Shares for an
                    indefinite period of time. Each stock certificate
                    representing Shares shall bear the following legends:

                    "THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED
                     UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
                     "ACT"). ANY TRANSFER OF SUCH SECURITIES SHALL BE
                     INVALID UNLESS A REGISTRATION STATEMENT UNDER THE ACT
                     IS IN EFFECT AS TO SUCH TRANSFER OR, IN THE OPINION OF
                     COUNSEL REASONABLY ACCEPTABLE TO GERON, SUCH
                     REGISTRATION IS UNNECESSARY FOR SUCH TRANSFER TO COMPLY
                     WITH THE ACT. THE SECURITIES REPRESENTED HEREBY ARE
                     SUBJECT TO THE TERMS OF THE COMMON STOCK PURCHASE
                     AGREEMENT, DATED APRIL 23, 2004. A COPY OF THE
                     AGREEMENT CAN BE OBTAINED FROM THE SECRETARY OF GERON."

               3.2  Limits on Sales. Transgenomic agrees that if it decides to
                    resell some or all of the Shares, it will do so only in an
                    appropriate manner based upon whether the shares are
                    registered or unregistered, i.e., on the Nasdaq National
                    Market or in a Rule 144A compliant transaction. Subject to
                    the foregoing restrictions, Transgenomic may sell or resell
                    the Shares in any lot size, or at any volume, desired by
                    Transgenomic. Notwithstanding the foregoing, Transgenomic
                    will not sell, assign, transfer, encumber, or in any manner
                    dispose of any of the Group 2 Shares until the earlier of
                    (a) such time as all Products ordered by Geron under
                    Addendum Agreement No. 5 have been delivered and accepted by
                    Geron in accordance with Addendum Agreement No. 5 and with
                    the Supply Agreement or (b) ninety (90) days after the
                    Effective Date of this Agreement.

     4.  REGISTRATION RIGHTS

               4.1  Geron agrees to make commercially reasonable best efforts to
                    file with the Securities and Exchange Commission (the
                    "Commission") within five (5) business days after the
                    Closing Date, a registration statement under the Act (the
                    "Registration Statement"), on Form S-3 or other appropriate
                    form, so as to permit a non-underwritten public offering and
                    resale of the Shares under the Act by Transgenomic. Geron
                    agrees to diligently pursue making the Registration
                    Statement effective. Geron will notify Transgenomic of the
                    effectiveness of the Registration Statement within one (1)
                    business day of receiving notice from the Commission.

               4.2  Geron will maintain the Registration Statement and any
                    post-effective amendment thereto filed under this Section 4
                    effective under the Act until the earliest of (i) the date
                    that none of the Shares covered by such Registration
                    Statement are issued and outstanding, (ii) the date that all
                    of the Shares have been sold pursuant to such Registration
                    Statement, (iii) the date Transgenomic receives an opinion
                    of counsel to Geron, which counsel shall be reasonably
                    acceptable to Transgenomic, that the Shares may be sold
                    under the provisions of Rule 144 without limitation as to
                    volume, (iv) the date that all Shares have been otherwise
                    transferred to persons who may trade such shares without
                    restriction under the Act, and Geron has delivered a new
                    certificate or other evidence of ownership for such
                    securities not bearing a restrictive legend, or (v) the date
                    all Shares may be sold at any time, without volume or manner
                    of sale limitations pursuant to Rule 144(k) or any similar
                    provision then in effect under the Act in the opinion of
                    counsel to Geron, which counsel shall be reasonably
                    acceptable to Transgenomic.

                                       2
<PAGE>

               4.3  Geron, at its expense, shall furnish to Transgenomic with
                    respect to the Shares registered under the Registration
                    Statement such reasonable number of copies of the
                    Registration Statement, prospectuses and preliminary
                    prospectuses in conformity with the requirements of the Act
                    and such other documents as Transgenomic may reasonably
                    request, in order to facilitate the public sale or other
                    disposition of all or any of the Shares by Transgenomic,
                    provided, however, that the obligation of Geron to deliver
                    copies of prospectuses or preliminary prospectuses to
                    Transgenomic shall be subject to the receipt by Geron of
                    reasonable assurances from Transgenomic that Transgenomic
                    will comply with the applicable provisions of the Act and of
                    such other securities or blue sky laws as may be applicable
                    in connection with any use of such prospectuses or
                    preliminary prospectuses.

               4.4  All fees, disbursements and out-of-pocket expenses and costs
                    incurred by Geron in connection with the preparation and
                    filing of the Registration Statement under Section 4.1 and
                    in complying with applicable securities and Blue Sky laws
                    (including, without limitation, all attorneys' fees of
                    Geron) shall be borne by Geron. Transgenomic shall bear the
                    cost of fees and expenses of Transgenomic's counsel.

               4.5  Geron will advise Transgenomic promptly after it shall
                    receive notice or obtain knowledge of the issuance of any
                    stop order by the Commission delaying or suspending the
                    effectiveness of the Registration Statement or of the
                    initiation of any proceeding for that purpose, and Geron
                    will use its commercially reasonable efforts to prevent the
                    issuance of any stop order or to obtain its withdrawal at
                    the earliest possible moment if such stop order should be
                    issued.

               4.6  With a view to making available to Transgenomic the benefits
                    of Rule 144 (or its successor rule) and any other rule or
                    regulation of the Commission that may at the time permit
                    Transgenomic to sell the Shares to the public without
                    registration, Geron covenants and agrees to: (i) make and
                    keep public information available, as those terms are
                    understood and defined in Rule 144, until the earliest of
                    (A) such date as all of the Shares may be resold pursuant to
                    Rule 144(k) or any other rule of similar effect or (B) such
                    date as all of the Shares shall have been resold; and (ii)
                    file with the Commission in a timely manner all reports and
                    other documents required of Geron under the Act and under
                    the Exchange Act of 1934, as amended.

               4.7  Transgenomic will cooperate with Geron in all respects in
                    connection with this Agreement, including timely supplying
                    all information reasonably requested by Geron (which shall
                    include all information regarding Transgenomic and proposed
                    manner of sale of the Shares required to be disclosed in any
                    Registration Statement) and executing and returning all
                    documents reasonably requested in connection with the
                    registration and sale of the Shares and entering into and
                    performing their obligations under any underwriting
                    agreement, if the offering is an underwritten offering, in
                    usual and customary form, with the managing underwriter or
                    underwriters of such underwritten offering. Nothing in this
                    Agreement shall obligate Transgenomic to consent to be named
                    as an underwriter in any Registration Statement.

     5.  INDEMNIFICATION.

               5.1  Geron agrees to indemnify and hold harmless Transgenomic
                    (and each person, if any, who controls Transgenomic within
                    the meaning of Section 15 of the Act, and each officer and
                    director of Transgenomic) against any and all losses,
                    claims, damages or liabilities (or actions or proceedings in
                    respect thereof), joint or several, directly or indirectly
                    based upon or arising out of (i) any untrue statement or
                    alleged untrue statement of any material fact contained in
                    the Registration Statement, any preliminary prospectus,
                    final prospectus or summary prospectus contained therein or
                    used in connection with the offering of the Shares, or any
                    amendment or supplement thereto, or (ii) any omission or

                                       3
<PAGE>

                    alleged omission to state a material fact required to be
                    stated therein or necessary to make the statements therein
                    not misleading; and Geron will reimburse each such
                    indemnified party for any legal or any other expenses
                    reasonably incurred by them in connection with
                    investigating, preparing, pursuing or defending any such
                    loss, claim, damage, liability, action or proceeding, except
                    insofar as any such loss, claim, damage, liability, action,
                    proceeding or expense (A) arises out of or is based upon an
                    untrue statement or alleged untrue statement or omission or
                    alleged omission made in the Registration Statement, any
                    such preliminary prospectus, final prospectus, summary
                    prospectus, amendment or supplement in reliance upon and in
                    conformity with written information furnished to Geron by
                    Transgenomic or such other person expressly for use in the
                    preparation thereof, (B) the failure of Transgenomic to
                    comply with its covenants and agreements contained in
                    Sections 7.1 or 7.5.2 hereof or (C) any misstatement or
                    omission in any prospectus that is corrected in any
                    subsequent prospectus that was delivered to Transgenomic
                    prior to the pertinent sale or sales by Transgenomic. Such
                    indemnity shall remain in full force and effect, regardless
                    of any investigation made by such indemnified party and
                    shall survive the transfer of the Shares by Transgenomic.

               5.2  Transgenomic agrees to indemnify and hold harmless Geron
                    (and each person, if any, who controls Geron within the
                    meaning of Section 15 of the Act, each officer of Geron who
                    signs the Registration Statement and each director of Geron)
                    from and against losses, claims, damages or liabilities (or
                    actions or proceedings in respect thereof), joint or
                    several, directly or indirectly based upon or arising out
                    of, (i) any failure of Transgenomic to comply with the
                    covenants and agreements contained in Sections 7.1 and 7.5.2
                    hereof or (ii) any untrue statement of a material fact
                    contained in the Registration Statement or any omission of a
                    material fact required to be stated in the Registration
                    Statement or necessary in order to make the statements in
                    the Registration Statement not misleading if such untrue
                    statement or omission was made in reliance upon and in
                    conformity with written information furnished to Geron by on
                    behalf of Transgenomic specifically for use in preparation
                    of the Registration Statement; provided, however, that
                    Transgenomic shall not be liable in any such case for (A)
                    any untrue statement or omission in the Registration
                    Statement, prospectus, or other such document which
                    statement is corrected by Transgenomic and delivered to
                    Geron prior to the sale from which such loss occurred, (B)
                    any untrue statement or omission in any prospectus which is
                    corrected by Transgenomic in any subsequent prospectus, or
                    supplement or amendment thereto, and delivered to Geron
                    prior to the sale or sales from which a loss or liability
                    arose, or (C) any failure by Geron to fulfill any of its
                    obligations under Section 5.1 hereof.

               5.3  Promptly after receipt by any indemnified person of a notice
                    of a claim or the beginning of any action in respect of
                    which indemnity is to be sought against an indemnifying
                    person pursuant to this Section 5, such indemnified person
                    shall notify the indemnifying person in writing of such
                    claim or of the commencement of such action, but the
                    omission to so notify the indemnifying party will not
                    relieve it from any liability which it may have to any
                    indemnified party under this Section 5 (except to the extent
                    that such omission materially and adversely affects the
                    indemnifying party's ability to define such action) or from
                    any liability otherwise than under this Section 5. Subject
                    to the provisions hereinafter stated, in case any such
                    action shall be brought against an indemnified person, the
                    indemnifying person shall be entitled to participate
                    therein, and, to the extent that it shall elect by written
                    notice delivered to the indemnified party promptly after
                    receiving the aforesaid notice from such indemnified party,
                    shall be entitled to assume the defense thereof, with
                    counsel reasonably satisfactory to such indemnified person.
                    After notice from the indemnifying person to such
                    indemnified person of its election to assume the defense
                    thereof, such indemnifying person shall not be liable to
                    such indemnified person for any legal expense subsequently
                    incurred by such indemnified person in connection with the
                    defense thereof, provided, however, that if there exists or
                    shall exist a conflict of interest that would make
                    inappropriate, in the reasonable opinion of counsel to the
                    indemnified person, for the same counsel to represent both
                    the indemnified person and such indemnifying person or any
                    affiliate or associate thereof, the indemnified person shall
                    be entitled to retain its own counsel at the expense of such
                    indemnifying person; provided, however, that no indemnifying
                    person shall be responsible for the fees and expenses of
                    more than on separate counsel (together with appropriate
                    local counsel) for all indemnified parties. In no event
                    shall any indemnifying person be liable in respect to any
                    amounts paid in settlement of any action unless the
                    indemnifying person shall have approved the terms of such

                                       4
<PAGE>

                    settlement. No indemnifying person shall, without the prior
                    written consent of the indemnified person, effect any
                    settlement of any pending or threatened proceeding in
                    respect of which any indemnified person is or could have
                    been a party and indemnification could have been sought
                    hereunder by such indemnified person, unless such settlement
                    includes an unconditional release of such indemnified person
                    from all liability on claims that are the subject matter of
                    such proceeding.

               5.4  The provisions of this Section 5 shall survive the
                    termination of this Agreement.

     6.  REPRESENTATIONS AND ACKNOWLEDGEMENT OF GERON.

         Geron hereby represents, warrants and covenants to Transgenomic as
         follow:

               6.1  Organization, Good Standing and Qualification. Geron is a
                    corporation duly organized, validly existing and in good
                    standing under the laws of the State of Delaware and has all
                    requisite corporate power and authority to carry on its
                    business as now conducted and as presently proposed to be
                    conducted. Geron is duly qualified to transact business and
                    is in good standing as a foreign corporation in each
                    jurisdiction in which the failure to so qualify would have a
                    material adverse effect on its business or properties.

               6.2  Authorization. All corporate action on the party of Company,
                    its officers, directors and stockholders necessary for the
                    authorization, execution and delivery of this Agreement, the
                    performance of all obligations of Company hereunder and the
                    authorization, issuance and delivery of the Shares has been
                    taken or will be taken prior to the Closing, and this
                    Agreement, when executed and delivered will constitute valid
                    and legally binding obligations of Geron, enforceable
                    against Geron in accordance with their terms, except as
                    limited by applicable bankruptcy, insolvency,
                    reorganization, moratorium, fraudulent conveyance and other
                    laws of general application affecting enforcement of
                    creditors' rights generally, as limited by laws relating to
                    the availability of specific performance, injunctive relief
                    or other equitable remedies.

               6.3  Valid Issuance of Common Stock. The Shares, when issued,
                    sold and delivered in accordance with the terms hereof for
                    the consideration expressed herein, will be duly and validly
                    authorized and issued, fully paid and nonassessable and free
                    of restrictions on transfer other than restrictions on
                    transfer under this Agreement and applicable state and
                    federal securities laws.

               6.4  Legal Proceedings and Orders. There is no action, suit,
                    proceeding or investigation pending or threatened against
                    Geron that questions the validity of this Agreement or the
                    right of Geron to enter into this Agreement or to consummate
                    this transactions contemplated hereby, nor is Geron aware of
                    any basis for any of the forgoing. Geron is neither a party
                    nor subject to the provisions of any order, writ,
                    injunction, judgment or decree of any court or government
                    agency or instrumentality that would affect the ability of
                    Geron to enter into this Agreement or to consummate the
                    transactions contemplated hereby.

     7.  REPRESENTATIONS AND ACKNOWLEDGMENTS OF TRANSGENOMIC.

         TRANSGENOMIC hereby represents, warrants, acknowledges and agrees that:

               7.1  Investment. Transgenomic is acquiring the Shares for
                    Transgenomic's own account, and not directly or indirectly
                    for the account of any other person. Transgenomic is
                    acquiring the Shares for investment and not with a view to
                    distribution or resale thereof, except in compliance with
                    the Act and any applicable state law regulating securities.

               7.2  Access to Information. Transgenomic has consulted with its
                    own attorney, accountant, or investment advisor as
                    Transgenomic has deemed advisable with respect to the
                    investment and has determined its suitability for
                    Transgenomic. Transgenomic has had the opportunity to ask
                    questions of, and to receive answers from, appropriate
                    executive officers of Geron with respect to the terms and
                    conditions of the transactions contemplated hereby and with
                    respect to the business, affairs, financial condition and
                    results of operations of Geron. Transgenomic has had access

                                       5
<PAGE>

                    to such financial and other information as is necessary in
                    order for Transgenomic to make a fully informed decision as
                    to investment in Geron, and has had the opportunity to
                    obtain any additional information necessary to verify any of
                    such information to which Transgenomic has had access.
                    Transgenomic acknowledges that neither Geron nor any of its
                    officers, directors, employees, agents, representatives, or
                    advisors have made any representation or warranty other than
                    those specifically expressed herein.

               7.3  Business and Financial Expertise. Transgenomic further
                    represents and warrants that it has such business or
                    financial expertise as to be able to evaluate its investment
                    in Geron and purchase of the Shares.

               7.4  Speculative Investment. Transgenomic acknowledges that the
                    investment in Geron represented by the Shares is highly
                    speculative in nature and is subject to a high degree of
                    risk of loss in whole or in part; the amount of such
                    investment is within Transgenomic's risk capital means and
                    is not so great in relation to Transgenomic's total
                    financial resources as would jeopardize the personal
                    financial needs of Transgenomic in the event such investment
                    were lost in whole or in part.

     7.5  Unregistered Securities. Transgenomic acknowledges that:

               7.5.1 Transgenomic must bear the economic risk of investment for
                    an indefinite period of time because the Shares have not
                    been registered under the Act and therefore cannot and will
                    not be sold unless they are subsequently registered under
                    the Act or an exemption from such registration is available.
                    Geron has made no agreements, covenants or undertakings
                    whatsoever to register any of the Shares under the Act,
                    except as provided in Section 4 above. Geron has made no
                    representations, warranties or covenants whatsoever as to
                    whether any exemption from the Act, including, without
                    limitation, any exemption for limited sales in routine
                    brokers' transactions pursuant to Rule 144 under the Act,
                    will become available and any such exemption pursuant to
                    Rule 144, if available at all, will not be available unless:
                    (i) a public trading market then exists in Geron's common
                    stock, (ii) Geron has complied with the information
                    requirements of Rule 144, and (iii) all other terms and
                    conditions of Rule 144 have been satisfied.

               7.5.2 Transfer of the Shares has not been registered or qualified
                    under any applicable state law regulating securities and,
                    therefore, the Shares cannot and will not be sold unless
                    they are subsequently registered or qualified under any such
                    act or an exemption therefrom is available. Geron has made
                    no agreements, covenants or undertakings whatsoever to
                    register or qualify any of the Shares under any such act.
                    Geron has made no representations, warranties or covenants
                    whatsoever as to whether any exemption from any such act
                    will become available.

               7.5.3 Transgenomic hereby certifies that it is an "Accredited
                    Investor" as that term is defined in Rule 501 under the Act.

     8.   TAX ADVICE. Transgenomic acknowledges that Transgenomic has not relied
          and will not rely upon Geron or Geron's counsel with respect to any
          tax consequences related to the ownership, purchase, or disposition of
          the Shares. Transgenomic assumes full responsibility for all such
          consequences and for the preparation and filing of all tax returns and
          elections which may or must be filed in connection with the Shares.

     9.   NOTICES. Any notice or other communication required or permitted
          hereunder shall be in writing and shall be deemed to have been duly
          given on the date of delivery if delivered personally or by facsimile,
          or one day, not including Saturdays, Sundays, or national holidays,
          after sending if sent by national overnight delivery service, or five
          days, not including Saturdays, Sundays, or national holidays, after
          mailing if mailed by first class United States mail, certified or
          registered with return receipt requested, postage prepaid, and
          addressed as follows:

                                       6
<PAGE>

          To Geron at:              Geron Corporation
                                    230 Constitution Drive
                                    Menlo Park, California  94025
                                    Attention: General Counsel
                                    Telephone:        (650) 473-7700
                                    Facsimile:        (650) 473-7750

          To Transgenomic at:       Transgenomic, Inc.
                                    12325 Emmet Street
                                    Omaha, Nebraska 68164
                                    Attention:  Law Department
                                    telephone:        (402) 452-5400
                                    facsimile:        (402) 452-5447

     10.  BINDING EFFECT. This Agreement shall be binding upon the heirs, legal
          representatives and successors of Geron and of Transgenomic; provided,
          however, that Transgenomic may not assign any rights or obligations
          under this Agreement.

     11.  GOVERNING LAW. This Agreement shall be governed by and construed in
          accordance with the laws of the State of California.

     12.  INVALID PROVISIONS. In the event that any provision of this Agreement
          is found to be invalid or otherwise unenforceable by a court or other
          tribunal of competent jurisdiction, such invalidity or
          unenforceability shall not be construed as rendering any other
          provision contained herein invalid or unenforceable, and all such
          other provisions shall be given full force and effect to the same
          extent as though the invalid and unenforceable provision was not
          contained herein.

     13.  COUNTERPARTS. This Agreement may be executed in any number of
          identical counterparts, each of which shall be deemed an original, but
          all of which together shall constitute one and the same instrument.

     14.  AMENDMENTS. This Agreement or any provision hereof may be changed,
          waived, or terminated only by a statement in writing signed by the
          party against whom such change, waiver or termination is sought to be
          enforced.

     15.  FUTURE COOPERATION. Each of the parties hereto agrees to cooperate at
          all times from and after the date hereof with respect to all of the
          matters described herein, and to execute such further assignments,
          releases, assumptions, amendments of the Agreement, notifications and
          other documents as may be reasonably requested for the purpose of
          giving effect to, or evidencing or giving notice of, the transactions
          contemplated by this Agreement.

     16.  ENTIRE AGREEMENT. This Agreement, the Common Stock Purchase Agreement
          dated as of January 21, 2004, and the Supply Agreement, including
          Addendum Agreement No. 5 thereto, constitute the entire agreement of
          the parties pertaining to the Shares and supersede all prior and
          contemporaneous agreements, representations, and understandings of the
          parties with respect thereto.

                                       7
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Common Stock
Purchase Agreement as of the date first above written.

                         Geron Corporation

                              /s/ David L. Greenwood
                         --------------------------------------------------
                         By:      David L. Greenwood
                         Title:   Chief Financial Officer and Senior Vice
                                  President, Corporate Development

                         Transgenomic, Inc.

                            /s/ Collin D'Silva
                         --------------------------------------------------
                         By:      Collin D'Silva
                         Title:   Chief Executive Officer

                                       8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00065-of-00352.parquet"}]]